September 9, 20100ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
